MMP9 and central nervous system cancer: Our results demonstrate that silencing of MMP9 in combination with uPAR/cathepsin B, which are over expressed in gliomas, affects the expression of γH2AX (NHEJ), RAD51 (HR) and lowers the activity of HIF-1α.